Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 7/20 | 0.33 |
| ▸ | CTSS | P25774 | 6/20 | 0.33 |
| ▸ | CTSB | P07858 | 5/20 | 0.33 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032979 | 1.00 | POLB (0.35) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL11452540 | 1.00 | POLB (0.35) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL11497665 | 1.00 | POLB (0.35) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL11497664 | 1.00 | POLB (0.35) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL8104152 | 0.77 | POLB (0.36) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL7187100 | 0.77 | POLB (0.36) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL9358907 | 0.77 | POLB (0.38) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL7187098 | 0.77 | POLB (0.36) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL9175389 | 0.77 | POLB (0.36) | POLBCTSKCTSSCTSBCTSL | |
| SCHEMBL8104148 | 0.77 | POLB (0.36) | POLBCTSKCTSSCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0817795-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES INC. (CA) | 1998-01-14 | — | — | EP | disclosed |
| WO-1997042170-A1 | A PROCESS FOR THE PREPARATION OF AZETIDINONES | BIOCHIMICA OPOS S.P.A. (IT) | 1997-11-13 | — | — | WO | disclosed |
| WO-1996032408-A1 | NOVEL 4-SUBSTITUTED-3-PEPTIDYL-AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE INHIBITOR | SYNPHAR LABORATORIES, INC. (US) | 1996-10-17 | — | — | WO | disclosed |
| US-4203896-A | WITH MERCURIC ACETATE AND ACETIC ACID, ACIDIC HYDROLYSIS OF N-PROPENYL GROUP | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4144232-A | Substituted azetidin-2-one antibiotics | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885CTSK 8/4885CTSS 1/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885CTSK 8/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.